2016 Parkinson's Research Year in Review

This is an archived file of an event that took place on December 15, 2016.

In this extended 90-minute webinar, we cover advances in our understanding of Parkinson's disease and development of new treatments.

Title: 2016 Parkinson's Research Year in Review

Duration: 1 hour 30 minutes

Continuing Medical Education Information for Health Care Professionals

MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: December 15, 2016
Date CME Credit No Longer Available: December 15, 2018

Learning Objectives
At the conclusion of this course, participants should be able to:

  1. Summarize the ongoing work in disease-modifying therapies for Parkinson's disease.
  2. Describe what is known about cellular connections underlying Parkinson's disease.
  3. Recognize Parkinson's symptomatic treatments that are at or near market.
  4. Discuss the state of research into tools and tests that could diagnose and track Parkinson's.
  5. List updates on research related to deep brain stimulation (DBS), stem cells and exercise.   

Target Audience
This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Faculty
Dave Iverson
No disclosures

Rachel Dolhun, MD
No disclosures

Todd Sherer, PhD
No disclosures

Gary Rafaloff
Advisory Role: Acorda Therapeutics; Takeda Pharmaceuticals; Biotie Therapies; PatientsLikeMe; Merck
Ownership Interests: Anavex Life Sciences

Register

Already Registered?

*Required Fields.

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.